US SEC Filings Daily Market Digest — August 17, 2026

17-08-2026

Foresite Capital Fund VI LP, along with related Foresite Capital entities and James B. Tananbaum, filed a Schedule 13D disclosing beneficial ownership of 9,181,328 shares of Latigo Biotherapeutics, Inc. common stock, representing 14.5% of the 63,238,030 shares outstanding as of August 7, 2026. The filing details a series of investments since September 2022, including purchases of Series A-2 and Series B convertible preferred stock, convertible promissory notes, and a recent IPO purchase, with Tananbaum serving on the issuer's board. The filing is a routine beneficial ownership disclosure and does not indicate any regulatory or trading action.

• · James B. Tananbaum is a member of the board of directors of Latigo Biotherapeutics.
• · None of the Reporting Persons has been convicted in any criminal proceeding or subject to securities-related civil proceedings in the last five years.
• · The filing is a preliminary event type of 'Major Shareholder' and was filed on August 17, 2026.
• · The issuer, Latigo Biotherapeutics, is a pharmaceutical preparations company incorporated in Delaware.

17-08-2026

M2i Global, Inc. filed a Form NT 10-Q with the SEC on August 17, 2026, notifying that it will be late in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The delay is attributed to unanticipated delays in compiling certain information necessary to complete the audit and prepare the filing in a timely manner. The company expects to file the overdue report within the standard five-day extension period.

• · The company has filed all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months.
• · It is not anticipated that any significant change in results of operations from the corresponding prior-year period will be reflected in the late Form 10-Q.

17-08-2026

Lixiang Education Holding Co., Ltd. announced the resignation of two independent directors, Teck Yong Heng and Yan Kit Lee, effective August 11, 2026, due to personal reasons and not due to any disagreement with the company. To fill the vacancies, the Board appointed Jing Luo and Yingyan Liang as independent directors on August 14, 2026. The new directors bring audit and financial reporting experience from KPMG and PwC, respectively.

• · Resignations effective August 11, 2026; appointments effective August 14, 2026.
• · Mr. Jing Luo, aged 35, is a Certified Public Accountant (New Hampshire) and non-practicing member of CICPA.
• · Ms. Yingyan Liang, aged 31, holds a Bachelor’s degree in Management from Guangdong University of Foreign Studies.

17-08-2026

Wise Group plc has acceded as a guarantor to its existing £2,000,000,000 Euro Medium Term Note (EMTN) Programme, as disclosed in an RNS dated August 17, 2026. This action strengthens the company's credit support for the programme but does not involve any new issuance or change in the programme size.

• · The filing is a Form 6-K submitted to the SEC on August 17, 2026.
• · The accession as guarantor is effective as of the date of the RNS.
• · No new notes were issued or programme size increased.

17-08-2026

Seto Wai Yue, CEO and Chairlady of Dreamland Ltd, filed an amended Schedule 13D/A disclosing beneficial ownership of 1,149,890 ordinary shares (1,069,890 Class A and 80,000 Class B), representing 32.99% of total outstanding ordinary shares as of August 7, 2026. The shares were acquired through a private placement from the issuer (580,000 Class A and 72,000 Class B) and a purchase from Imperial Vision Fund SPC (320,000 Class A), all at $3.75 per share. The filing indicates increased ownership and investment intent, but no specific plans for changes in control or major corporate actions.

• · Class B shares carry 12 votes per share, while Class A shares carry 1 vote per share.
• · The reporting person's percentage of aggregate voting power is not disclosed, but due to Class B shares' higher voting rights, it may exceed 32.99%.
• · The acquisitions were completed on July 7, 2026 (private placement) and August 6, 2026 (purchase from Imperial Vision Fund).
• · The reporting person holds the shares for investment purposes and has no current plans for changes in control or major corporate actions.

17-08-2026

LogicMark, Inc. filed a Form 12b-25 Notification of Late Filing (NT 10-Q) for its quarterly report for the period ended June 30, 2026. The delay is attributed to the demands of a strategic transaction announced on August 3, 2026, including the negotiation of a Merger Agreement with Langham Project, LLC and Langham Merger Sub, Inc., and the preparation of a preliminary proxy statement, which diverted management and finance personnel attention. The company does not anticipate any significant change in results of operations for the quarter compared to the prior year.

• · The late filing is for Form 10-Q for the quarter ended June 30, 2026.
• · The Merger Agreement is dated July 31, 2026.
• · The company expects to file the Form 10-Q within 5 calendar days of the prescribed due date.
• · The registrant confirms all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months have been filed.
• · No significant change in results of operations for the quarter is anticipated compared to the prior year period.

17-08-2026

Wellgistics Health, Inc. (WGRX) reported a net loss of $18.4M for Q2 2026, widening from a $6.7M loss in Q2 2025, as net revenues collapsed 77% YoY to $1.8M from $7.8M. While the company raised $14.2M in convertible notes and increased cash to $2.5M, total liabilities rose to $52.3M and the accumulated deficit deepened to $137.1M, resulting in a negative stockholders' equity of $19.5M.

• · Gross margin fell to 10.2% in Q2 2026 from 6.5% in Q2 2025, but improved to 10.6% in H1 2026 from 6.4% in H1 2025.
• · Allowance for credit losses increased to $1.0M as of June 30, 2026 from $0.8M at December 31, 2025.
• · Reserve for inventory obsolescence rose to $6.5M as of June 30, 2026 from $6.4M at December 31, 2025.
• · The company recorded a $8.9M loss on extinguishment of debt and a $0.8M loss on contract termination fee in H1 2026.
• · Stock-based compensation decreased sharply to $2.6M in H1 2026 from $28.7M in H1 2025.
• · Interest expense, net increased to $3.6M in H1 2026 from $2.3M in H1 2025.
• · Cash used in operating activities increased to $6.3M in H1 2026 from $3.4M in H1 2025.
• · The company issued $14.2M in convertible notes during H1 2026, with $12.7M in fair value of PIPE and placement agent warrants.
• · Total current liabilities exceeded total current assets by $33.8M as of June 30, 2026, indicating a significant working capital deficit.
• · Goodwill remained unchanged at $14.2M, while other intangible assets decreased slightly to $9.7M.

17-08-2026

Centene announced a planned CFO transition: Drew Asher will step down as CFO on December 31, 2026, and retire from the company at the end of 2027. Chris Neczypor, formerly CFO of Lincoln Financial, will join in September and assume the role of EVP and CFO on January 1, 2027. The company reaffirmed its FY2026 adjusted diluted EPS guidance of greater than $4.80.

• · Chris Neczypor will join Centene in September 2026 and work alongside Drew Asher until assuming the CFO role on January 1, 2027.
• · Drew Asher will remain with the company until his retirement at the end of 2027 to support strategic initiatives and ensure a smooth transition.
• · Centene reaffirms its FY2026 adjusted diluted EPS guidance of greater than $4.80 and all associated 2026 full-year guidance metrics from its July 28, 2026 Q2 earnings release.

17-08-2026

Interactive Strength Inc. (TRNR) filed a definitive proxy statement (DEF 14A) on August 17, 2026, for a Special Meeting of Stockholders to be held on August 28, 2026. The meeting seeks stockholder approval for several proposals, including the issuance of 20% or more of outstanding common stock upon conversion of existing preferred stock and new Series F Preferred Stock issued to STEPR, Inc. shareholders, as well as an amendment to the 2023 Stock Incentive Plan to add 5,000,000 shares and an automatic share increase provision. The company also proposes granting the Board authority to effect a reverse stock split at a ratio between 1-for-4 and 1-for-100, with an aggregate limit of 1-for-100, to be completed within one year of the record date.

• · The Special Meeting will be held on August 28, 2026 at 10:00 a.m. Central Time at 1005 Congress Ave, Suite 925, Austin, Texas 78701.
• · Record date for voting is August 13, 2026.
• · The Board recommends a vote 'FOR' all six proposals.
• · Proposals include approval of issuance of 20% or more of outstanding shares upon conversion of Existing Preferred Stock, Series F Preferred Stock (for STEPR acquisition), convertible notes, and warrants.
• · The Reverse Stock Split proposal allows a ratio range from 1-for-4 up to 1-for-100, with an aggregate limit of 1-for-100, to be completed within one year of the record date.
• · Stockholders may vote by Internet, telephone, or mail; beneficial owners must obtain a legal proxy from their broker.

17-08-2026

Endeavour Silver Corp. filed a Form 6-K with the SEC on August 17, 2026, submitting a press release dated the same day. The filing is a routine report of a foreign private issuer, with no specific financial or operational details disclosed in the 6-K itself.

• · Filing type: Form 6-K (foreign private issuer report)
• · Filing date: August 17, 2026
• · Commission file number: 001-33153
• · Principal executive office: Vancouver, British Columbia, Canada
• · Exhibit 99.1 is a press release dated August 17, 2026

17-08-2026

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) reported the termination of CEO Michael K. Handley effective August 16, 2026, and the appointment of Lisa Wolf as Chief Operating Officer (retaining her CFO role). The company also entered into a letter agreement with 3i, LP to issue 1,500 Series B Preferred Shares and warrants for $1.5 million, and will enter into a royalty agreement giving 3i and other purchasers 5% of gross revenue from subsidiary Velocity Bioworks for 10 years. Stockholders approved a reverse stock split authorization (ratio between 1:5 and 1:50) at a special meeting with 46.75% quorum.

• · CEO Michael K. Handley was terminated effective August 16, 2026; no reason was disclosed.
• · Lisa Wolf, age 64, was appointed COO on August 16, 2026, while remaining CFO. She has over 30 years of experience and previously served as interim CFO from October 2024.
• · The Series B Preferred Purchase Agreement originally dated April 29, 2025, was assigned and amended on December 9, 2025.
• · The royalty agreement grants 3i and other purchasers 5% of gross revenue from Velocity Bioworks for 10 years.
• · At the special meeting, 1,243,030 votes were cast in favor of the reverse stock split authorization, 697,127 against, with 678 abstentions.
• · Proposal 2 (adjournment authority) was also approved but not used because Proposal 1 passed.
• · The company's common stock trades on Nasdaq under the symbol VBIO.
• · The company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

17-08-2026

TTM Technologies announced a definitive agreement to acquire Epiq Solutions for $1.1 billion in an all-cash transaction, expected to close in late Q3 2026. The acquisition is projected to be immediately accretive to Adjusted EBITDA margin and accretive to Non-GAAP Diluted EPS during 2028, with a synergy-adjusted transaction multiple of 17.4x expected 2027 EBITDA. However, the company faces risks including regulatory approvals, financing conditions, and integration challenges, and the forward-looking statements caution that actual results may differ materially.

• · The acquisition is expected to close in late Q3 2026, subject to regulatory approvals and customary conditions.
• · Committed financing from JPMorgan, Bank of America, and Barclays.
• · Epiq Solutions is a portfolio company of Veritas Capital, founded in 2009, headquartered in Rolling Meadows, IL, with operations in Frederick, MD, and Montreal, QC.
• · TTM plans to invest over $400 million through 2029 for growth across U.S. manufacturing facilities due to munitions demand surge.
• · The company expects to reduce net leverage from 2.3x to within 1.5x-1.7x within 12-18 months post-close.
• · Conference call scheduled for August 17, 2026 at 12:30 p.m. EDT.

17-08-2026

Welsbach Technology Metals Acquisition Corp. (WTMAU) filed its 10-Q for the quarter ended June 30, 2026, reporting its first-ever revenues of $1.6M for Q2 and $3.5M for the first half of 2026, following a business combination that closed in early 2026. However, the company posted a net loss of $11.9M in Q2 2026 (improved from a $40.9M loss in Q2 2025) and a staggering $452.2M net loss for the first six months of 2026, driven largely by a $423.6M non-cash change in fair value of financial instruments. Cash and cash equivalents fell sharply from $11.7M at year-end 2025 to $5.3M at June 30, 2026, while total assets surged to $95.1M from $22.5M, reflecting the acquisition of operating businesses.

• · The company completed a business combination in early 2026, resulting in a reverse recapitalization and the acquisition of operating businesses, which added goodwill of $58.9M and intangible assets of $6.3M.
• · Selling, general and administrative expenses surged to $12.1M in Q2 2026 (from $2.9M in Q2 2025) and $28.2M in H1 2026 (from $5.7M in H1 2025), reflecting the expanded operations.
• · The company reported a gross loss of $115K in Q2 2026, though a gross profit of $329K for H1 2026.
• · Change in fair value of financial instruments was a negative $423.6M in H1 2026, compared to a negative $48.9M in H1 2025, primarily due to the revaluation of derivative liabilities and CPU Share Allocation Obligations.
• · Net cash used in operating activities increased to $14.8M in H1 2026 from $4.5M in H1 2025.
• · The company raised $19.4M from the issuance of convertible debentures in H1 2026.
• · Total stockholders' deficit improved dramatically from $654.9M at year-end 2025 to $18.9M at June 30, 2026, due to the conversion of preferred units and settlement of liabilities with common stock.
• · The company had no revenue in the prior-year periods (Q2 2025 and H1 2025), as it was a pre-operational SPAC.
• · Non-trade accounts payable of $47.6M and accrued expenses of $27.4M represent significant current liabilities as of June 30, 2026.
• · The company's accumulated deficit grew to $1.13B as of June 30, 2026, from $678.8M at December 31, 2025.

17-08-2026

FDCTECH, INC. filed a Form NT 10-Q late filing notice for its quarterly report for the period ended June 30, 2026, citing delays in receiving tax information from its foreign subsidiaries in Malta, the UK, Australia, Seychelles, Cyprus, and Mauritius. The company expects to file the Form 10-Q within the five-day grace period. Despite the filing delay, the company provided preliminary unaudited results showing a dramatic improvement: for the three months ended June 30, 2026, total revenues surged to $17,472,536 from $5,419,791 in the prior-year period, and net income attributable to shareholders was $7,710,931 versus a net loss of $437,923. However, the prior-year periods do not include the results of Alchemy International Ltd. (AIL) and related subsidiaries acquired in October 2025, making the year-over-year comparisons not directly comparable.

• · The company operates through subsidiaries in Malta, the United Kingdom, Australia, Seychelles, Cyprus, and Mauritius.
• · The late filing is due to incomplete tax information from foreign subsidiaries, not due to any operational or financial issues.
• · The company completed the acquisition of a 99.90% equity interest in Alchemy International Ltd. on October 29, 2025.
• · Prior-year periods (three and six months ended June 30, 2025) do not include AIL results, making comparisons non-comparable.
• · The company expects to file the Form 10-Q by the fifth calendar day following the prescribed due date.
• · All other periodic reports required under the Exchange Act during the preceding 12 months have been filed.

17-08-2026

Duos Technologies Group, Inc. filed a Form NT 10-Q on August 17, 2026, indicating it will be late in filing its Quarterly Report for the period ended June 30, 2026. The delay is attributed to the company's inability to complete its financial statements and other disclosures without unreasonable effort or expense, and its independent auditor requires additional time to complete the review. The company does not anticipate any significant change in results of operations from the corresponding prior-year period.

• · The filing was due on August 14, 2026, for smaller reporting companies.
• · The company expects to file the Quarterly Report no later than the fifth calendar day following the prescribed due date (i.e., by August 19, 2026).
• · The company has filed all other periodic reports required under the Exchange Act during the preceding 12 months.
• · The company does not anticipate any significant change in results of operations from the corresponding prior-year period.

17-08-2026

AsiaStrategy (SORA) entered into two share purchase agreements on August 15, 2026, to sell 100% of its subsidiary AsiaStrategy Topwin SG Pte. Ltd. for a total of $10 million. The subsidiary's sole asset is a 7.07% stake in Astra Enterprise Public Company Limited (SET:ASTR). The buyers are entities affiliated with company insiders: Sora Valiant Limited (beneficially owned by co-CEO Jason Kin Hoi Fang) and Asia Empire Development Limited (where director Mary Wong is a director). The sale is structured as two separate 50% stakes, each for $5 million, with 20% due within one month and the remaining 80% within one year.

• · The subsidiary was originally formed to participate in a tender offer for DV8 (now ASTR) completed on August 22, 2025.
• · The sale is motivated by regulatory burdens under the U.S. Investment Company Act and contractual sale restrictions.
• · Closing is not contingent on full payment; buyer becomes legal owner upon transfer of shares.
• · Payments can be made in USD, USDT (1:1), or HKD (at 7.8 HKD per USD).
• · The agreements are governed by New York law with exclusive jurisdiction in New York courts.

17-08-2026

Regen BioPharma Inc reported its quarterly results for the period ended June 30, 2026. The derivative liability decreased from $2,079,618 to $1,901,963, while accounts receivable from related parties increased to $287,147. Accrued expenses rose to $2,007,987, and the company took on new notes payable of $132,503, while unearned income declined to $1,243,691.

• · Derivative liability valuation assumptions: risk-free interest rate 3.98%, expected term (0.0001) – 0.10 years, expected volatility 1226.67%, expected dividends 0.
• · Accrued payroll taxes increased from $28,753 to $38,153; accrued interest increased from $476,434 to $517,754; accrued payroll remained at $1,206,630; accrued rent decreased from $85,000 to $79,027; other accrued expenses increased from $41,413 to $166,423.
• · Notes payable to Trillium Partners, LP of $132,503 was new as of June 30, 2026 (none at September 30, 2025).

17-08-2026

Barrick Mining Corp filed a Form 6-K with the SEC on August 17, 2026, as a foreign private issuer. The filing contains only the company's contact information and no financial or operational updates.

17-08-2026

Caledonia Mining Corporation Plc filed a Form 6-K with the SEC on August 17, 2026, for the month of August 2026, attaching a press release dated the same day. The filing is a routine foreign issuer report and does not contain any financial results or material updates beyond the press release itself.

• · Press release is dated August 17, 2026.
• · The company's principal executive office is at 2 Mulcaster Street, St Helier, Jersey JE2 3NJ.
• · Commission File Number: 001-38164.
• · The registrant files annual reports under cover of Form 20-F.

17-08-2026

Quince Therapeutics, Inc. plans to hold a special meeting of stockholders to seek approval for the issuance of common stock upon conversion of Series C Preferred Stock and exercise of warrants, which could represent more than 20% of outstanding shares and potentially result in a change of control. The company filed unaudited pro forma condensed consolidated financial information as of June 30, 2026, adjusted for the conversion, but cautions that these projections are preliminary and may not reflect actual financial condition. No specific financial figures or period-over-period comparisons were provided in this filing.

• · The special meeting will address approval under Nasdaq Listing Rules 5635(a), (b), and (d).
• · The conversion of Series C Preferred Stock and exercise of warrants could result in a change of control of the company.
• · Unaudited pro forma financial information is based on the quarter ended June 30, 2026, and does not reflect all expected costs.
• · A preliminary proxy statement was filed with the SEC on July 31, 2026.

17-08-2026

Tower Semiconductor Ltd. filed its unaudited condensed interim consolidated financial statements for the period ended June 30, 2026, along with management's discussion and analysis. The filing provides a comprehensive view of the company's financial condition and results of operations for the first half of 2026.

• · The filing includes unaudited condensed interim consolidated financial statements as of June 30, 2026.
• · Management's Discussion and Analysis of Financial Condition and Results of Operations is included as Exhibit 99.2.
• · The report was signed by Nati Somekh, Corporate Secretary, on August 17, 2026.

17-08-2026

Liberty Defense Holdings, Ltd. filed its Form 6-K with the SEC on August 17, 2026, reporting unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2026. The filing includes management's discussion and analysis and certifications by the CEO and CFO. No specific financial figures or performance trends are disclosed in the cover filing itself.

• · Filing includes unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2026 and 2025.
• · Includes Management's Discussion and Analysis for the period ended June 30, 2026.
• · CEO and CFO certifications (Form 52-109FV2) for the interim period ended June 30, 2026 are included as exhibits.

17-08-2026

Stonehage Fleming Financial Services Holdings Ltd filed its Form 13F-HR for the quarter ended June 30, 2026, disclosing $2,931,904,020 in total equity holdings across 276 positions. The portfolio is heavily concentrated in large-cap technology and financial services, with top holdings including Netflix ($115.5M), S&P Global ($158.8M), Mastercard ($154.3M), and McDonald's ($123.8M). The filing reflects a diversified strategy with significant exposure to gold ETFs and municipal bond ETFs, alongside core equity positions.

• · The filing was signed by Stuart Parkinson, Group CEO, on August 13, 2026.
• · The portfolio includes 276 positions with a total market value of $2,931,904,020.
• · Top 10 holdings by value: Alphabet Class C ($284.3M), Broadcom ($223.4M), KLA Corp ($170.0M), S&P Global ($158.8M), Mastercard ($154.3M), Cadence Design ($153.7M), Arthur J. Gallagher ($137.5M), Amazon ($131.6M), Stryker ($127.5M), McDonald's ($123.8M).
• · Significant gold exposure through multiple ETFs: SPDR Gold Shares ($8.5M), iShares Gold Trust ($2.5M), iShares Gold Trust Micro ($4.2M), ETFS Gold Trust ($4.8M), Sprott Physical Gold Trust ($0.35M).
• · Municipal bond ETF holdings: iShares National Muni ETF ($11.7M), iShares California Muni ETF ($5.9M), iShares New York Muni ETF ($1.0M).
• · Crypto exposure via iShares Bitcoin Trust ($0.4M) and iShares Ethereum Trust ($32,673).
• · Small positions in speculative names: Peloton Interactive ($59), Reliance Global Group ($9), MoneyHero Limited warrants ($186).
• · No period-over-period comparison data available as this is a single-quarter filing.

17-08-2026

Alterity Therapeutics Ltd filed a Form 6-K with the SEC for August 2026, primarily disclosing a report under the Australian Takeovers Panel Guidance Note 20. The filing is a procedural update to incorporate the disclosure into the company's existing registration statements on Form S-8 and Form F-3. No financial results or material changes to the company's operations were reported.

• · The filing is being incorporated by reference into the company's SEC registration statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
• · The document references a disclosure under the Australian Takeovers Panel Guidance Note 20.

17-08-2026

XORTX Therapeutics Inc. filed a Form 6-K with the SEC for August 2026, including its condensed interim consolidated financial statements and management discussion and analysis for the six months ended June 30, 2026. The filing is a routine periodic report by a foreign private issuer, providing unaudited interim financial results. No specific financial figures or performance metrics are disclosed in the filing text itself.

• · The filing includes Condensed Interim Consolidated Financial Statements for the six months ended June 30, 2026.
• · The filing includes Management Discussion and Analysis for the six months ended June 30, 2026.
• · The filing includes Co-CEO Certificates and CFO Certificate.

17-08-2026

Gravity Acquisition Corp., a blank check company, filed an S-1/A registration statement for its initial public offering of 25,000,000 units at $10.00 per unit, with an over-allotment option of 3,750,000 units. The offering includes a private placement of 267,500 units to initial shareholders for $2,675,000. The company has 9,583,333 founder shares issued to the sponsor and others, with 1,250,000 subject to forfeiture. The company must complete a business combination within 15 months (extendable to 21 months) or redeem public shares, and rights will expire worthless if no deal is completed.

• · The company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
• · The initial business combination must be completed within 15 months from the closing of the offering, extendable to 21 months.
• · If the company fails to complete a business combination, public shareholders may redeem their shares for a pro rata portion of the trust account, but rights will expire worthless.
• · Founder shares are subject to transfer restrictions until six months after the business combination or earlier under certain conditions, including if the share price reaches $12.00 for 20 trading days within 30 days after 150 days post-combination.
• · The sponsor and initial shareholders have agreed to waive redemption rights on founder shares and private shares in connection with the business combination and liquidation.
• · Maxim Group LLC is acting as underwriter and will receive representative shares equal to 3.5% of gross proceeds (875,000 shares).
• · The offering includes an over-allotment option of 3,750,000 units, which if exercised, would increase the number of units and shares outstanding.
• · The company will file a Current Report on Form 8-K with audited balance sheet reflecting receipt of gross proceeds after closing.
• · Separate trading of ordinary shares and rights will not commence until the Form 8-K is filed.

17-08-2026

Goodvision AI Inc. filed an S-4/A registration statement on August 17, 2026, providing updated financial statements for the six months ended June 30, 2026, and the fiscal year ended December 31, 2025. The filing details the company's financial position, including a net loss of $1.5 million for the six months ended June 30, 2026, compared to a net loss of $0.8 million for the same period in 2025, indicating a worsening loss trend. The filing also includes information on related party transactions, share issuances, and the company's business combination activities.

• · The filing is an S-4/A registration statement related to a business combination.
• · The company had $20.0 million in total assets and $5.0 million in total liabilities as of June 30, 2026.
• · Revenue grew 25% year-over-year in H1 2026, but net loss increased 87.5% over the same period.
• · The company's net loss for FY 2025 was $3.0 million, triple the $1.0 million loss in FY 2024.
• · Total liabilities increased 66.7% from $3.0 million at year-end 2025 to $5.0 million by mid-2026.
• · The filing includes details on related party transactions with GV Assets Holdings Limited and Waterdrip Investment Ltd.
• · The company had 100 employees as of the filing date.

17-08-2026

Blue Edge Capital, LLC filed its quarterly 13F-HR for the period ending June 30, 2026, reporting a diversified portfolio of 137 equity holdings with a total market value of approximately $832.8 million. The firm's largest positions are concentrated in broad-market ETFs, including the Vanguard Growth ETF ($75.8M), Vanguard Value ETF ($68.8M), and iShares Core MSCI Europe ETF ($36.2M), alongside significant individual stock holdings in Apple ($19.0M), Caterpillar ($14.0M), and Amazon ($11.7M). The filing reflects a balanced approach across U.S. large-cap, international, and fixed-income ETFs, with no single equity position dominating the portfolio.

• · The portfolio includes 137 equity positions as of June 30, 2026.
• · The largest single stock holdings are Apple ($19.0M), Caterpillar ($14.0M), and Amazon ($11.7M).
• · The portfolio has a significant allocation to fixed-income ETFs, including iShares Broad USD Invm Grd Cor ($21.9M), iShares Barclays TIP Bond ($21.5M), and Janus Henderson Mortgage-Backed ($17.5M).
• · International exposure is achieved through ETFs such as iShares Core MSCI Europe ($36.2M), Vanguard FTSE Pacific ($16.5M), and Vanguard Emerging Market ($12.8M).
• · The filing was signed by Margaret Fretz, Chief Compliance Officer, on August 14, 2026.

17-08-2026

Bleichroeder Acquisition Corp. II filed a definitive additional proxy statement supplement (DEFA14A) on August 17, 2026, to update Annex B with the full text of the Reincorporation Plan of Merger and to correct clerical errors in Annex H-1 (New Pasqal Articles of Association) for its proposed business combination with Pasqal. The supplement does not change the terms of the proxy statement/prospectus dated August 5, 2026. The merger is expected to be effective on August 27, 2026.

• · The supplement updates Annex B with the full text of the Cayman and French Reincorporation Plans of Merger.
• · Annex H-1 is updated to correct clerical errors in the New Pasqal Articles of Association.
• · The Reincorporation Merger is part of Proposal No. 2, and the New Pasqal Articles are part of Proposals No. 4 and 5.
• · The Business Combination Agreement has been amended three times: Amendment No. 1 (May 26, 2026), Amendment No. 2 (June 25, 2026), and Amendment No. 3 (July 22, 2026).
• · The Merger is expected to be effective on August 27, 2026.
• · The Merging Company's registered office is in the Cayman Islands; the Surviving Company's registered office is in Paris, France.
• · The Surviving Company will continue as a French société anonyme after the Merger.

17-08-2026

Jacobs Equity LLC filed its quarterly 13F-HR for the period ending June 30, 2026, disclosing a diversified portfolio of equity holdings. The filing shows significant positions in major ETFs and individual stocks, with top holdings including Schwab Strategic Trust US LRG CAP ETF (265,723 shares), Schwab Strategic Trust EMRG MKTEQ ETF (124,291 shares), and Vanguard Intl Equity Index F FTSE Europe ETF (124,470 shares). The portfolio reflects a broad market exposure with a mix of U.S. and international equities, sector-specific ETFs, and select individual stocks, but no period-over-period comparisons are available as this is a single filing.

• · The portfolio includes a significant allocation to Schwab ETFs, with the US LRG CAP ETF being the largest position by shares (265,723).
• · International exposure is notable through Vanguard FTSE Europe ETF (124,470 shares) and Vanguard FTSE Pacific ETF (51,042 shares).
• · Individual stock holdings include major companies like JPMorgan Chase (23,273 shares), Apple (3,599 shares), and NVIDIA (8,650 shares).
• · The filing is for the period ending June 30, 2026, and was submitted on August 17, 2026.

17-08-2026

Diginex Ltd (DGNX) filed a Form 6-K on August 17, 2026, disclosing a condition in a transaction agreement requiring the company to have sufficient cash, as determined by the Sellers' Representative, to repay all past, current, outstanding, and contingent liabilities (including termination payments and introducer fees) and to cover operating expenses through at least December 31, 2026. This condition suggests the company is undergoing a significant transaction, likely an acquisition or merger, with a focus on ensuring post-completion liquidity.

• · The cash sufficiency condition is determined by the Sellers’ Representative, not by Diginex itself.
• · Liabilities to be repaid include those from termination or resignation of officers, employees, or independent contractors, as well as introducer fees.
• · Operating expenses must be covered up to at least December 31, 2026, indicating a specific post-completion runway requirement.

17-08-2026

EIG Asset Management, LLC filed its quarterly 13F-HR report with the SEC for the period ending June 30, 2026, disclosing its holdings as of that date. The filing shows the firm held positions in Diversified Energy Co (common stock) and USA Compression Partners LP (common units), with both positions reported as zero shares held with sole voting and dispositive power. This indicates EIG Asset Management may have fully exited these positions during the quarter.

• · Filing type: 13F-HR (institutional investment manager holdings report)
• · Period of report: June 30, 2026
• · Filed as of date: August 17, 2026
• · Filer: EIG Asset Management, LLC (formerly EIG Asset Management Company, LLC, name changed August 15, 2014)
• · Both positions reported with 0 shares held, suggesting complete liquidation of those holdings
• · No new positions or other securities were disclosed in this filing

17-08-2026

Cosan S.A. announced a series of corporate simplification measures, including the resignation of its CFO and Chief Legal Officer, a call for an EGM to approve the spin-off of Radar II, and the voluntary delisting of its ADSs from the NYSE. The company also introduced a new debt service interest coverage guidance target of 0.8x to 1.2x by end of FY2026. While the restructuring aims to reduce costs and streamline operations, the delisting and executive departures signal significant strategic shifts.

• · The spin-off of Radar II will not result in any increase in Cosan's share capital or dilution of shareholders.
• · The effective date of the Radar II spin-off, if approved, is October 1, 2026.
• · The new CFO, José Cezário Menezes de Barros Sobrinho, previously held the same position at Rumo S.A., a Cosan investee.
• · The legal department will now report to the new CFO.
• · The delisting from the NYSE does not immediately affect Cosan's SEC registration; a timeline for deregistration will be disclosed later.
• · The guidance for debt service interest coverage is expected to converge to 0.8x to 1.2x by end of FY2026.
• · The Fiscal Council issued a unanimous favorable opinion on the Radar II spin-off on August 13, 2026.

17-08-2026

Almitas Capital LLC filed its quarterly 13F-HR for the period ending June 30, 2026, reporting a portfolio value of approximately $417.4 million across 130 positions. The filing shows a diversified mix of closed-end funds, BDCs, REITs, and small-cap biotech/pharma holdings, with top positions including Fidelity Wise Origin Bitcoin Fund ($69.7M), ASA Gold and Precious Metals ($32.7M), and BlackRock Mun Target Term Trust ($33.8M). The filing does not provide prior-period comparisons, so no period-over-period changes can be assessed.

• · The portfolio includes a significant allocation to closed-end funds and business development companies (BDCs), reflecting an income-oriented strategy.
• · Top equity holdings by value include Fidelity Wise Origin Bitcoin Fund ($69.7M), BlackRock Mun Target Term Trust ($33.8M), ASA Gold and Precious Metals ($32.7M), and Cannae Holdings ($10.7M).
• · Biotech/pharma positions include Amylyx Pharmaceuticals ($17.5M), Design Therapeutics ($14.9M), AN2 Therapeutics ($7.1M), and Lyell Immunopharma ($8.2M).
• · The filing includes a small position in Cohen & Steers Quality Income Realty Fund rights expiring July 15, 2026 (50,000 shares, $745 value).
• · No period-over-period comparisons are available as the 13F-HR only reports current quarter holdings.

17-08-2026

Ma Investment Partnership, LP disclosed its Q2 2026 13F-HR filing, reporting a portfolio value of approximately $561.4 million as of June 30, 2026. The fund's largest disclosed positions include SanDisk Corp ($227.4M), NVIDIA Corp ($80.0M), and Advanced Micro Devices ($58.1M). The filing shows a concentrated portfolio of 13 equity holdings, with significant exposure to semiconductor and technology stocks.

• · The filing is a 13F-HR for the period ending June 30, 2026, filed on August 17, 2026.
• · All 13 positions are listed as sole voting and dispositive power held by the fund.
• · The portfolio is heavily concentrated in technology and semiconductor sectors, with SanDisk alone representing ~40% of total reported value.
• · No period-over-period comparisons are available as this is a snapshot filing without prior quarter data.

17-08-2026

Tenon Medical, Inc. filed Amendment No. 1 to its Form S-3 registration statement with the SEC on August 14, 2026, to register securities for potential future offerings. The company, a medical device firm focused on SI Joint fusion, highlights its two systems (Catamaran and SImmetry+) and the August 2025 acquisition of SiVantage and SIMPL Medical assets. The filing includes forward-looking statements and risk factors, but no specific offering amounts or financial data are disclosed.

• · Company incorporated in Delaware on June 19, 2012, headquartered in Los Gatos, CA.
• · FDA clearance for Catamaran System received in 2018.
• · National commercial launch of Catamaran System in October 2022.
• · Acquisition of SiVantage and SIMPL Medical assets completed in August 2025.
• · SI Joint fusion market penetration estimated at 5-7%.
• · Open SI Joint fusion procedure requires 6 to 12-inch incision.
• · SI Joint is approximately 2-4mm wide.
• · Company focuses on three commercial opportunities: primary SI Joint procedures, revision procedures, and SI-Joint fusion adjunct to spine fusion.

17-08-2026

Council Ring Capital, LLC filed its quarterly 13F-HR report with the SEC for the period ending June 30, 2026, disclosing its institutional holdings. The filing indicates a single holding in MBB Public Markets I LLC, with no shares or value reported, suggesting a minimal or zero position as of the reporting date.

• · The filing is for the period ending June 30, 2026, and was filed on August 17, 2026.
• · The filer is Council Ring Capital, LLC, a Delaware LLC with EIN 872646439.
• · The filing contains only one entry: MBB Public Markets I LLC, with 0 shares and 0 value.
• · The report was signed by Andrew J. Mills, Manager, on August 14, 2026.

17-08-2026

Grupo Aval Acciones y Valores S.A. has made a regularly scheduled interest payment on its Seventh Issuance of Notes in the Colombian market on August 14, 2026. This is a routine debt servicing disclosure with no new financial results, regulatory actions, or material changes reported.

• · Interest payment relates to notes issued in Pesos in the Colombian market.
• · Filing is a Form 6-K for the month of August 2026.
• · The registrant files annual reports under Form 20-F.

17-08-2026

Fayez Sarofim & Co filed its quarterly 13F-HR for the period ending June 30, 2026, reporting a total portfolio value of approximately $42.54 billion. The filing reveals a concentrated portfolio with top holdings in Apple Inc. ($2.51B), Alphabet Inc. ($1.69B), Chevron Corp. ($573.5M), Coca-Cola Co. ($736.0M), and Abbott Laboratories ($183.9M). The fund also holds significant positions in Berkshire Hathaway, Blackstone, and Broadcom, reflecting a long-term, large-cap value-oriented strategy.

• · The filing includes 536 holdings with a total market value of $42,539,907,326.
• · Top holdings include Apple Inc. ($2.51B), Alphabet Inc. Class C ($1.69B), Coca-Cola Co. ($736.0M), Chevron Corp. ($573.5M), and Abbott Laboratories ($183.9M).
• · The fund holds multiple share classes of Berkshire Hathaway (Class A and Class B) with combined value over $400M.
• · Significant positions in financials: BlackRock ($439.2M), Blackstone ($248.1M), Bank of New York Mellon ($191.4M), CME Group ($190.9M).
• · Energy exposure includes Chevron ($573.5M), ConocoPhillips ($37.2M), Diamondback Energy, and Alliance Resource Partners.
• · Technology holdings include Broadcom ($295.5M), ASML Holding ($725.2M), and Apple ($2.51B).
• · Healthcare positions include AbbVie ($464.6M), Abbott Laboratories ($183.9M), Medtronic, and Amgen.
• · The fund has a notable position in Canadian Pacific Kansas City ($203.9M).
• · No period-over-period comparisons are available as this is a single-quarter filing.

17-08-2026

Dogness (International) Corporation issued 3,050,000 Class A common shares upon cash exercise of outstanding warrants on August 13, 2026, increasing total shares outstanding to 8,551,658. Concurrently, the company amended its share acquisition agreement to reduce the target equity interest from 19.5% to 6.735% and imposed a nine-month lock-up on the newly issued shares. The warrant exercise and amendment reflect a significant dilution event and a scaled-back acquisition target.

• · The warrants were exercised for cash, providing immediate liquidity to the company.
• · The lock-up period on the newly issued shares lasts nine months after transfer and registration of the reduced target equity.
• · The amendment waived the beneficial ownership limitation and removed the 61-day waiting period for warrant exercise.
• · The target equity transfer deadline is November 6, 2026.

17-08-2026

Redwood Investment Management, LLC filed its Form 13F-HR for the quarter ended June 30, 2026, disclosing $100.9 million in total reported holdings across 306 equity and ETF positions. The portfolio is heavily weighted toward passive ETFs, with the top three holdings being Vanguard S&P 500 ETF ($12.97M), Invesco S&P 500 Momentum ETF ($10.31M), and LeaderShares AlphaFactor US Co ETF ($6.13M). While the filing shows a diversified mix of large-cap ETFs and individual stocks, it does not provide prior-period comparisons, so performance trends cannot be assessed.

• · The filing is for the quarter ended June 30, 2026, and was filed on August 17, 2026.
• · The filer is Redwood Investment Management, LLC, based in Scottsdale, Arizona.
• · The portfolio includes 306 positions with a total reported value of $100,889,700.
• · The top three holdings by value are Vanguard S&P 500 ETF ($12,969,100), Invesco S&P 500 Momentum ETF ($10,307,000), and LeaderShares AlphaFactor US Co ETF ($6,130,500).
• · The filing does not include prior-period data, so no period-over-period comparisons are available.

17-08-2026

Seven Fleet Capital Management LP reported a 13F-HR filing for the quarter ended June 30, 2026, disclosing 114 equity holdings with a total market value of approximately $605.9 million. The portfolio is heavily concentrated in biotechnology and pharmaceutical companies, with top positions including Tango Therapeutics ($95.7M), CG Oncology ($134.0M), and Revolution Medicines ($45.3M). The filing reflects a significant allocation to small- and mid-cap biotech names, with many positions held in both sole and shared voting authority.

• · Filing type: 13F-HR for period ending June 30, 2026
• · Filing date: August 17, 2026
• · Firm address: 960 San Clemente Way, Mountain View, CA 94043
• · SEC file number: 028-26709
• · Central Index Key: 0002092021
• · The portfolio is entirely composed of equity securities (no options or convertible bonds listed)
• · Many positions are split between sole voting authority and other (shared) authority, indicating co-investment or managed accounts
• · Largest single position by value: CG Oncology Inc (sole + other = $134.0M)
• · Second largest: Tango Therapeutics Inc (sole + other = $95.7M)
• · Third largest: Revolution Medicines Inc (sole + other = $45.3M)

17-08-2026

Ming Shing Group Holdings Ltd (MSW) filed its 20-F annual report for the fiscal year ended March 31, 2026, reporting a 56.8% decline in total revenue to $14.6M from $33.9M in FY2025. The company recorded a net loss of $5.8M, slightly wider than the $5.7M loss in the prior year, driven by a gross loss of $2.7M (vs. $1.3M gross loss in FY2025). The company diversified into trading of wines and spirits, generating $3.6M in revenue with a 39.1% gross margin, but this was insufficient to offset the sharp decline in its core wet trades works segment, where revenue fell 67.5% to $11.0M.

• · Public sector projects gross loss margin worsened from -13.3% in FY2025 to -83.7% in FY2026.
• · Private sector projects swung from a 0.9% gross profit margin in FY2025 to a -18.8% gross loss margin in FY2026.
• · General and administrative expenses decreased 31.3% YoY to $2.8M, partially offsetting revenue decline.
• · Interest expense net decreased 31.9% YoY to $0.35M.
• · Income tax expense was $13,835 in FY2026 vs. an income tax credit of $80,154 in FY2025.

17-08-2026

Parvin Asset Management, LLC filed its quarterly 13F-HR report for the period ending June 30, 2026, disclosing 320 holdings with a total market value of approximately $127.47 million. The portfolio is diversified across sectors, with notable positions in gold and silver miners, consumer staples, and technology. No negative or flat metrics are reported in this filing.

• · The filing was submitted on August 17, 2026, for the quarter ended June 30, 2026.
• · The report was signed by Todd H. Keating, Chief Operating Officer.
• · All positions are listed as sole voting and dispositive authority, with no shared or none authority.
• · The portfolio includes a mix of common stocks, ETFs, and one call option (KraneShares Trust KWEB).

17-08-2026

Proficio Capital Partners LLC filed its quarterly 13F-HR for the period ending June 30, 2026, disclosing 691 equity positions with total reported holdings of approximately $2.79 billion. The portfolio is heavily concentrated in mega-cap technology stocks, with top holdings including Apple Inc. ($36.97M), Alphabet Inc. Class C ($27.45M), Amazon.com Inc. ($22.84M), Eli Lilly & Co. ($17.47M), and Alphabet Inc. Class A ($15.41M). The firm also maintains significant positions in ETFs such as the Alps ETF Trust Alerian MLP ($32.25M) and the First Trust Exchange Traded FD RBA Industrial ETF ($44.49M).

• · The filing includes 691 positions with a total value of $2,786,023,691.
• · Top 10 holdings by value: Apple ($36.97M), Alphabet C ($27.45M), Amazon ($22.84M), Eli Lilly ($17.47M), Alphabet A ($15.41M), Broadcom ($9.88M), Berkshire Hathaway B ($9.08M), Dell Technologies ($8.17M), Advanced Micro Devices ($6.45M), Blackstone ($5.88M).
• · Significant ETF positions include Alps ETF Trust Alerian MLP ($32.25M), First Trust RBA Industrial ETF ($44.49M), and Bitwise Funds Trust Prof Curr De ETF ($70.54M).
• · The portfolio includes a mix of large-cap growth stocks, value stocks, and sector-specific ETFs, with no single position exceeding 2.7% of total holdings.
• · No period-over-period comparison data is available as this is a single-period filing.

17-08-2026

IWAC Holding Company Inc. filed a Form 12b-25 Notification of Late Filing with the SEC, indicating it will be unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 by the prescribed due date. The company cites the need for additional time to finalize financial statements and anticipates filing within the five-day extension period. Additionally, the company has not yet filed its Form 10-Q for the quarter ended March 31, 2026, which it expects to file before or simultaneously with the June Form 10-Q.

• · The company has not filed its Form 10-Q for the quarter ended March 31, 2026, and anticipates filing it before or simultaneously with the June Form 10-Q.
• · The company expects to file the June Form 10-Q within the five-day extension period provided by Rule 12b-25.
• · The contact person for the notification is Matthew Malriat, CEO, at (917) 397-7625.

17-08-2026

KM Capital Management Ltd. filed its Form 13F-HR for the period ending June 30, 2026, reporting a total portfolio value of approximately $212.8 million across 48 equity holdings. The portfolio is heavily weighted toward iShares and Dimensional ETFs, with top positions in the Dimensional US Equity Market ETF ($36.3M), iShares Core S&P Total Stock Market ETF ($22.5M), and iShares Long Term Muni ETF ($22.7M). The filing shows a diversified, predominantly passive strategy with significant exposure to US equities, municipal bonds, and international markets, but no prior-period comparison is available to assess performance trends.

• · The portfolio includes a small allocation to iShares Bitcoin Trust ($1.3M), indicating modest exposure to cryptocurrency.
• · The largest single holding by value is the Dimensional US Equity Market ETF at $36.3M, representing about 17% of the total portfolio.
• · Municipal bond ETFs (iShares Long Term Muni, National Muni, Short Maturity Muni, and J.P. Morgan Ultra-Short Muni) collectively total approximately $24.8M, or about 12% of the portfolio.
• · International exposure includes Dimensional International Value ETF ($14.2M), iShares Core MSCI Emerging Markets ($12.3M), and iShares Europe ETF ($2.9M).
• · The filing does not include any prior-period data, so no quarter-over-quarter or year-over-year comparison is possible.

17-08-2026

GreenPower Motor Company Inc. filed its Form 6-K with the SEC for the month of August 2026, including financial statements and management's discussion and analysis for the period ended June 30, 2026. The filing incorporates these documents by reference into the company's registration statements on Form F-3 and Form S-8. No specific financial figures or performance metrics are disclosed in the cover filing itself, so a balanced assessment of performance cannot be made from this document alone.

• · The filing includes Exhibits 99.1 (Financial Statements), 99.2 (MD&A), 99.3 (CEO Certification), and 99.4 (CFO Certification) for the period ended June 30, 2026.
• · These exhibits are incorporated by reference into the company's Form F-3 (No. 333-276209) and Form S-8 (No. 333-261422) registration statements.
• · The report was signed by CFO Michael Sieffert on August 14, 2026.